Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 18/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30827426 | 1.00 | HTR4 (0.57) | HTR4MCL1POLBHTT | |
| Hydrochloric Acid SCHEMBL9020820 | 0.98 | HTR4 (0.56) | HTR4MCL1POLBHTT | |
| SCHEMBL7804705 | 0.86 | HTR4 (0.57) | HTR4 | |
| SCHEMBL30337559 | 0.86 | HTR4 (0.56) | HTR4POLBHTT | |
| SCHEMBL7806682 | 0.80 | KDM4E (0.55) | HTR4 | |
| SCHEMBL1372897 | 0.79 | DAO (0.62) | MCL1 | |
| SCHEMBL5823619 | 0.79 | MCL1 (0.62) | HTR4MCL1POLB | |
| SCHEMBL30086987 | 0.79 | DAO (0.62) | MCL1 | |
| SCHEMBL18537084 | 0.79 | HTR4 (0.49) | HTR4 | |
| SCHEMBL2010294 | 0.78 | POLB (0.46) | HTR4POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11642339-B2 | Methods of treating symptoms of gastroparesis using velusetrag | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-05-09 | — | — | US | claimed |
| US-20190030022-A1 | METHODS OF TREATING SYMPTOMS OF GASTROPARESIS USING VELUSETRAG | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-01-31 | — | — | US | claimed |
| EP-2419104-B1 | COMBINATIONS OF 5-HT4 RECEPTOR AGONISTS AND ACETYLCHOLINESTERASE INHIBITORS FOR TREATMENT OF COGNITIVE DISORDERS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-11-08 | — | — | EP | claimed |
| US-9630960-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-04-25 | — | — | US | claimed |
| US-20160376264-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-12-29 | — | — | US | claimed |
| CN-105832735-A | 5-HT4 receptor agonist compounds for treatment of cognitive disorders | 施万生物制药研发IP有限责任公司 | 2016-08-10 | — | — | CN | claimed |
| US-9402840-B2 | Crystalline form of a quinolinone-carboxamide compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-02 | — | — | US | claimed |
| US-20160095849-A1 | CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-04-07 | — | — | US | claimed |
| US-9126994-B2 | Crystalline form of a quinolinone-carboxamide compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-09-08 | — | — | US | claimed |
| US-20140256769-A1 | CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND | THERAVANCE, INC. (US) | 2014-09-11 | — | — | US | claimed |
| EP-1735304-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | Theravance, Inc. (US) | 2006-12-27 | — | — | EP | claimed |
| WO-2006108127-A2 | CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND | THERAVANCE, INC. (US) | 2006-10-12 | — | — | WO | claimed |
| US-20060229332-A1 | crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or solvate thereof; treating disease associated with 5-HT4 receptor activity; gastrointestinal tract disorder | THERAVANCE, INC. | 2006-10-12 | — | — | US | claimed |
| WO-2006094063-A1 | QUINOLINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2006-09-08 | — | — | WO | claimed |
| US-20060199839-A1 | Quinolinone compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2006-09-07 | — | — | US | claimed |
| WO-2006052640-A1 | 5-HT4 RECEPTOR AGONIST COMPOUNDS | THERAVANCE, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| US-20060100236-A1 | For therapy of disorder of reduced motility of gastrointestinal tract, chronic constipation, functional dyspepsia, delayed gastric emptying, gastroesophageal reflux disease, gastroparesis, diabetic and iodiopathic gastropathy, post-operative ileus, intestinal pseudo-obstruction, irritable bowel syndrome | THERAVANCE, INC. (US) | 2006-05-11 | — | — | US | claimed |
| US-20060100426-A1 | Quinolinone-carboxamide compounds | THERAVANCE, INC. | 2006-05-11 | — | — | US | claimed |
| WO-2005100350-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2005-10-27 | — | — | WO | claimed |
| US-20050228014-A1 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2005-10-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199839-A1 | Quinolinone compounds as 5-HT4 receptor agonists | HTR4, HTR5A, HTR1A | HTR4 1/4885MCL1 3282/4885POLB 3223/4885 |
| US-20050228014-A1 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR5A, HTR1A | HTR4 1/4885MCL1 2866/4885POLB 3728/4885 |
| US-20140256769-A1 | CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND | HTR5A, HTR4, HTR2C | HTR4 2/4885MCL1 3125/4885POLB 3157/4885 |
| US-20160095849-A1 | CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND | HTR5A, HTR4, HTR2C | HTR4 2/4885MCL1 3125/4885POLB 3157/4885 |
| US-20160376264-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | HTR4 1/4885MCL1 2866/4885POLB 3728/4885 |
| US-11642339-B2 | Methods of treating symptoms of gastroparesis using velusetrag | SLC10A2, GIPR, VIPR2 | HTR4 298/4885MCL1 4823/4885POLB 3447/4885 |
| US-20060229332-A1 | crystalline hydrochloride salt of 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[(R)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide or solvate thereof; treating disease associated with 5-HT4 receptor activity; gastrointestinal tract disorder | HTR4, HTR5A, HTR2C | HTR4 1/4885MCL1 3986/4885POLB 2591/4885 |
| US-20060100236-A1 | For therapy of disorder of reduced motility of gastrointestinal tract, chronic constipation, functional dyspepsia, delayed gastric emptying, gastroesophageal reflux disease, gastroparesis, diabetic and iodiopathic gastropathy, post-operative ileus, intestinal pseudo-obstruction, irritable bowel syndrome | GIPR, GPR4, GPR119 | HTR4 8/4885MCL1 4877/4885POLB 3377/4885 |
| US-20060100426-A1 | Quinolinone-carboxamide compounds | HTR4, HTR5A, HTR2C | HTR4 1/4885MCL1 2718/4885POLB 3514/4885 |
| US-20190030022-A1 | METHODS OF TREATING SYMPTOMS OF GASTROPARESIS USING VELUSETRAG | SLC10A2, GIPR, VIPR2 | HTR4 298/4885MCL1 4823/4885POLB 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.